4D Molecular Therapeutics Announces Interim Clinical Data From Ongoing Phase 1/2 Clinical Trial Of Intravitreal 4D-150 For Wet Age-Related Macular Degeneration
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection